Research Papers:

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar _, Elisabeth Eppard, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Carl Diedrich Schlenkhoff, Florian Gärtner, Sebastian Rogenhofer and Markus Essler

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:12477-12488. https://doi.org/10.18632/oncotarget.7245

Metrics: PDF 2827 views  |   HTML 4641 views  |   ?  


Hojjat Ahmadzadehfar1, Elisabeth Eppard1, Stefan Kürpig1, Rolf Fimmers2, Anna Yordanova1, Carl Diedrich Schlenkhoff1, Florian Gärtner1, Sebastian Rogenhofer3, Markus Essler1

1Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

2Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany

3Department of Urology, University Hospital Bonn, Bonn, Germany

Correspondence to:

Hojjat Ahmadzadehfar, e-mail: [email protected], [email protected]

Keywords: PSMA, 177Lu, prostate cancer, radioligand therapy, PSA

Received: October 26, 2015    Accepted: January 27, 2016    Published: February 08, 2016


Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75.2 years (range: 64–82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17–2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79.1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68.2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7245